WINT

Windtree Therapeutics Inc

WINT, USA

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

https://windtreetx.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
WINT
stock
WINT

Will SHAK stock split attract more investors - Global Markets & AI Based Buy/Sell Signal Reports bollywoodhelpline.com

Read more →
WINT
stock
WINT

What consensus target says about Barratt Redrow plc (3BA) stock - 2025 Sector Review & Reliable Intraday Trade Plans bollywoodhelpline.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$4

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.00

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

249.25 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-181.05 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.30% of the total shares of Windtree Therapeutics Inc

1.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1722%)

since

2025/07/31

2.

Fidelity Extended Market Index

(0.0614%)

since

2025/07/31

3.

Jane Street Group LLC

(0.0498%)

since

2025/06/30

4.

Tower Research Capital LLC

(0.0075%)

since

2025/06/30

5.

Spartan Total Market Index Pool G

(0.0053%)

since

2025/07/31

6.

Bank of America Corp

(0.0004%)

since

2025/06/30

7.

SBI Securities Co Ltd

(0.0001%)

since

2025/06/30

8.

UBS Group AG

(0.0001%)

since

2025/06/30

9.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

10.

BlackRock Inc

(0%)

since

2025/03/31

11.

Renaissance Technologies Corp

(0%)

since

2025/03/31

13.

Geode Capital Management, LLC

(0%)

since

2025/03/31

14.

Cubist Systematic Strategies, LLC

(0%)

since

2025/03/31

15.

Two Sigma Investments LLC

(0%)

since

2025/03/31

16.

XTX Topco Ltd

(0%)

since

2025/03/31

17.

Activest Wealth Management

(0%)

since

2025/03/31

18.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

20.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.08

EPS Estimate

-0.06

EPS Difference

-1.02

Surprise Percent

-1700%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.